13FGuru
Sign in with Google Sign in with Discord

NASDAQ · Health Care

Indivior INDV

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders.

Sources StockAnalysis company profile stockanalysis.com
Biotechnology: Pharmaceutical Preparations

Company profile

Business mix

  • The company develops medicines to treat substance use disorders.
  • The company also offers OPVEE nasal spray for opioid overdose reversal.

Current key questions

  • Can the company's products, services, or pipeline expand adoption within drug manufacturers - specialty & generic?
  • How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
  • Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?
Holders 1 Current sample portfolio
Public mentions 0 Videos / interviews / letters
Valuation snapshot
PE 33.6 FCF 2.89% Buyback 5.04%
2000-01-01

Current firm holders

Firm Weight Value Filing period
Oaktree Capital Management Howard Marks 0.1% $7.0M 2026-03-31

Recent trading changes over the last 2 quarters

Last 1 quarters Last 2 quarters Last 3 quarters Last 4 quarters
Net buyers 0 Last 2 13F filing periods
Net reducers 2 Last 2 13F filing periods
Unchanged holders 0 Share count unchanged
Increase amount $0 Estimated from net added shares
Reduction amount $42.9M Estimated from net reduced shares
Net share change / base shares -17.9% -46,263,835 / 259,139,263
Soros Fund Management George Soros 2 filing periods
13F 2025-12-31 Filed 2026-02-13
Minor reduction Shares -14.7% 13F value change +$8.8M
13F 2026-03-31 Filed 2026-05-15
Sold out Shares -100.0% 13F value change -$41.4M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 1,353,865 Last 2 periods -1,353,865 (-100.0%) Total shares 0 Value $0
Oaktree Capital Management Howard Marks 2 filing periods
13F 2025-12-31 Filed 2026-02-17
Major reduction Shares -97.2% 13F value change +$244.4M
13F 2026-03-31 Filed 2026-05-15
Major increase Shares 2894.6% 13F value change -$248.1M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 257,785,398 Last 2 periods -44,909,970 (-17.4%) Total shares 212,875,428 Value $7.0M

Recent mentions

No public mentions.